The FDA defines a biosimilars as biologic products approved because they're highly similar to existing medicines, but there's a lot more to understand. A biosimilar is a manufactured biologic ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

If the Trump White House is serious about its push to make medicines more affordable, it should ensure CMS officials never ...

The biologics market in the United States has grown an average of 12.5% annually over the past 5 years, according to data from the IQVIA Institute. 1 By 2026, these medications are expected to account ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

In 2024, the use of generic and biosimilar medicines saved $467 billion for the United States health-care system and the patients who use it, according to a recent report by the Association for ...

Please provide your email address to receive an email when new articles are posted on . It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S. Byooviz ...

A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...